LB931 Treatment of chronic graft-versus-host disease with combination extracorporeal photopheresis and the ROCK2 inhibitor belumosudil can reverse sclerodermatous changes
Swallow M, Chang J, Carlson K, Odell I, Girardi M. LB931 Treatment of chronic graft-versus-host disease with combination extracorporeal photopheresis and the ROCK2 inhibitor belumosudil can reverse sclerodermatous changes. Journal Of Investigative Dermatology 2024, 144: s163. DOI: 10.1016/j.jid.2024.06.1104.Peer-Reviewed Original ResearchTreatment of chronic graft-versus-host diseaseChronic graft-versus-host diseaseGraft-versus-host diseaseExtracorporeal photopheresisSclerodermatous changesPhotopheresisBelumosudil